Preventive and therapeutic strategies for respiratory syncytial virus infection

Respiratory syncytial virus (RSV) remains an important cause of pneumonitis in infants and in the elderly and immunosuppressed. Passive immunoprophylaxis of high-risk infants with the humanised monoclonal antibody palivizumab reduces RSV-related hospitalisation and admission to intensive care units...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current Opinion in Pharmacology 2001-10, Vol.1 (5), p.497-503
Hauptverfasser:	Vujovic, Olga, Mills, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use bronchiolitis Humans immunisation Immunization, Passive immunoprophylaxis immunotherapy Palivizumab respiratory syncytial virus Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - immunology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Infections - virology Respiratory Syncytial Virus Vaccines - immunology Respiratory Syncytial Virus Vaccines - therapeutic use Respiratory Syncytial Viruses - drug effects Respiratory Syncytial Viruses - immunology ribavirin RSV-IGIV
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!